Trials / Terminated
TerminatedNCT00104338
Study of FK778 in Renal Transplant Recipients With Untreated BK Nephropathy
A Phase 2, Proof of Concept, Randomized, Open-label, Two-arm, Parallel Group, Multi-center Study to Assess the Efficacy and Safety of FK778 Compared With Standard Care in Renal Transplant Recipients With Untreated BK Nephropathy
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (planned)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and effectiveness of a new oral immunosuppressant agent compared to standard care in renal transplant patients diagnosed with BK nephropathy.
Detailed description
The purpose of this study is to assess the efficacy and safety of FK778 compared with standard care in renal transplant recipients with newly diagnosed and untreated BK nephropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FK778 |
Timeline
- Start date
- 2005-01-01
- Completion
- 2006-08-01
- First posted
- 2005-02-25
- Last updated
- 2012-06-07
Locations
21 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00104338. Inclusion in this directory is not an endorsement.